-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

379 Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Program: Oral and Poster Abstracts
Type: Oral
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions
Hematology Disease Topics & Pathways:
Research, Translational Research, Treatment Considerations, Biological therapies, Adverse Events, Technology and Procedures, Transplantation (Allogeneic and Autologous), Omics technologies
Saturday, December 7, 2024: 4:00 PM

Shuntaro Ikegawa, MD, PhD1*, Takeru Asano, MD, PhD2*, Bohoon Shim3*, Mehdi Borji, MS4*, Haesook T. Kim, PhD3,5, Shuqiang Li, PhD1*, Kenneth J. Livak, PhD1*, Gordon J. Freeman, PhD1,6*, Xia Bu, PhD1*, Roger Belizaire, MD, PhD6,7, Jennifer Whangbo, MD, PhD6,8, Roman M. Shapiro, MD1,6, Mahasweta Gooptu, MD6,9, Rizwan Romee, MD1,6, Sarah Nikiforow, MD, PhD1,6, Vincent T. Ho, MD1,6*, Corey S. Cutler, MD, MPH1,6, Joseph H. Antin, MD1,6, Robert J. Soiffer, MD1,6, John Koreth, MD, MBBS, PhD, DPhil1,6, Jeremy M. Simon, PhD3,5*, Catherine J. Wu, MD1,6* and Jerome Ritz, MD1,6

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Japanese Red Cross Society Himeji Hospital, Himeji, Japan
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4Broad Institute of MIT and Harvard, Cambridge, MA
5Harvard T.H. Chan School of Public Health, Boston, MA
6Harvard Medical School, Boston, MA
7Department of Pathology, Dana-Farber Cancer Institute, Inc., Boston, MA
8Boston Children Hospital, Boston, MA
9Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA

Background. After allogeneic hematopoietic cell transplant (allo-HCT), impaired recovery of CD4 regulatory T cells (Treg) is associated with the development of chronic GVHD (cGVHD). Previous clinical trials have shown that daily administration of low-dose (LD) interleukin-2 (IL-2) selectively expands circulating CD4Treg in all patients with steroid-refractory cGVHD, with approximately 50% of adult patients having clinical improvement. Although some predictors of clinical response have been identified, CD4Treg-intrinsic factors associated with clinical improvement still need to be elucidated.

PD-1 is a coinhibitory receptor that attenuates the activation and function of effector T cells. However, the role of PD-1 on CD4Treg is not fully understood. LD IL-2 therapy induces expression of PD-1 on CD4Treg, and PD-1 has a critical role in maintaining CD4Treg expansion during LD IL-2 treatment (Asano T et al, Blood 2017). This prompted us to conduct a detailed analysis of PD-1+CD4Treg and their relevance to clinical outcomes after LD IL-2 therapy.

Methods. To identify intrinsic Treg factors associated with clinical outcome, we analyzed serial cryopreserved PBMC samples from 21 patients with steroid-refractory cGVHD who were enrolled in a clinical trial combining extracorporeal photopheresis (ECP) and LD IL-2 therapy. Phenotypic changes in PBMC during treatment were monitored by mass cytometry. To elucidate CD4Treg heterogeneity, we also used single-cell RNA sequencing to characterize CD4Treg (CD3+CD4+CD25+CD127low) derived from cryopreserved PBMC of responders (n = 4) and non-responders (n = 6) four weeks after initiation of LD IL-2.

Results. ECP therapy alone had minimal impact on CD4Treg, but additional treatment with LD IL-2 markedly altered multiple CD4Treg populations, including a PD-1+CD4Treg cluster characterized as highly activated, immune suppressive, and proapoptotic. This effect was also observed in CD4Treg from healthy individuals stimulated with LD IL-2 alone in vitro. After in vitro LD IL-2 stimulation, PD-1+CD4Treg suppressed the proliferation of effector T cells more effectively than PD-1-CD4Treg. Although PD-1+CD4Treg clusters increased from baseline in clinical responders, the increase of PD-1+CD4Treg clusters was not different between responders and non-responders.

Unsupervised clustering of single-cell RNAseq data identified six distinct groups of CD4Treg, including a naïve-like subset (PDCD1-low with high expression of CCR7, TCF7, and LEF1), an exhausted subset (PDCD1+ with high expression of LAG3, CTLA4, and TIGIT), and an effector subset (PDCD1+ with high expression of CCR4 and IKZF2). The exhausted CD4Treg subset also featured expression of cytotoxicity markers (NKG7, GZMA, and GZMK). When comparing LD IL-2 responders to non-responders, we found that the ratio of effector/exhausted Treg was significantly higher in patients with clinical response (p = 0.019).

To further explore differences within CD4Treg associated with clinical improvement of cGVHD, we performed pseudo-bulk differential gene expression analyses. We found that there were many individual genes whose expression was significantly associated with clinical response, particularly in an effector CD4Treg subset in non-responders. Gene set enrichment analysis revealed that pathways related to cytokine signaling, including interferon (STAT1, IFNGR2, IRF1, SOCS1, and SOCS3), were enriched in non-responders in multiple CD4Treg subsets. In responders, IFITM3 was upregulated among the effector and exhausted CD4Treg cells; this gene was recently reported as a negative feedback regulator of the IFNg-induced STAT1 pathway in CD4Treg. These results suggest that activation of the IFNg-induced STAT1 pathway in CD4Treg may have promoted expansion of more exhausted CD4Treg in clinical non-responders.

Conclusions. In summary, LD IL-2 therapy in patients with cGVHD induced multiple CD4Treg populations, including PD-1+CD4Tregs. However, PD-1+CD4Tregs are heterogeneous, including both exhausted and effector subsets, and the balance between these two CD4Treg subsets after IL-2 therapy appears to correlate with clinical improvement after LD IL-2 therapy. Additionally, activation of the STAT1 pathway is one of the putative CD4Treg-intrinsic factors associated with lack of clinical response to LD IL-2 therapy. Validation studies and functional assays are ongoing.

Disclosures: Livak: MBQ Pharma Inc.: Membership on an entity's Board of Directors or advisory committees. Freeman: Geode: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; Simcere of America: Consultancy; Santa Ana Bio: Consultancy; Bioentre: Consultancy, Current equity holder in private company; IOME: Consultancy; GV20: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; IgM: Consultancy, Current equity holder in publicly-traded company; Nextpoint: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; iTEOS: Consultancy, Current equity holder in publicly-traded company; Novartis: Patents & Royalties: PD-L1/PD-1 pathway; Eli Lilly: Patents & Royalties: PD-L1/PD-1 pathway; Leica: Patents & Royalties: PD-L1/PD-1 pathway; Dako: Patents & Royalties: PD-L1/PD-1 pathway; Boehringer-Ingelheim: Patents & Royalties: PD-L1/PD-1 pathway; Merck MSD: Patents & Royalties: PD-L1/PD-1 pathway; Bristol-Myers Squibb: Patents & Royalties: PD-L1/PD-1 pathway; AstraZeneca: Patents & Royalties: PD-L1/PD-1 pathway; Merck KGA: Patents & Royalties: PD-L1/PD-1 pathway; Roche: Patents & Royalties: PD-L1/PD-1 pathway; Invaria: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. Whangbo: Vor Biopharma: Current Employment. Shapiro: Miltenyi: Other: Paid lecture; Hansa Biopharma: Consultancy. Gooptu: Syndax: Consultancy, Other: Travel expenses. Romee: CRISPR Therapeutics: Research Funding; Skyline Therapeutics: Research Funding; Glycostem: Membership on an entity's Board of Directors or advisory committees. Ho: Alexion: Consultancy; Omeros: Research Funding; CareDx: Research Funding; Jazz: Research Funding; Allovir: Consultancy. Cutler: Oxford Immune Algorithmics: Current equity holder in private company; Astellas: Consultancy; Cimeio: Current equity holder in publicly-traded company; Sanofi: Consultancy; Incyte: Consultancy; Angiocrine: Other: DSMB; Novartis: Consultancy; Rigel: Consultancy; Allovir: Other: DSMB; Syndax: Consultancy. Soiffer: Neovii: Consultancy; Jasper: Consultancy; Smart Immune: Consultancy; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Vor Biopharma: Consultancy; Amgen: Consultancy; Astellas: Consultancy. Koreth: Biopharm Communications LLC: Honoraria; Tr1X Inc: Consultancy; Cugene Inc: Membership on an entity's Board of Directors or advisory committees; Mallinckrodt Inc: Membership on an entity's Board of Directors or advisory committees; Clinigen Labs Inc: Research Funding; Iovance Inc: Research Funding; Equillium Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gentibio Inc: Consultancy; Biolojic Design Inc: Consultancy; Cue Biopharma Inc: Consultancy; Miltenyi Biotec GMBH: Research Funding; Regeneron Inc: Research Funding; BMS Inc: Research Funding; CSL Behring Inc: Consultancy. Wu: Repertoire: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; BioNtech, Inc: Current equity holder in publicly-traded company; Adventris: Membership on an entity's Board of Directors or advisory committees; Aethon Therapeutics: Membership on an entity's Board of Directors or advisory committees. Ritz: Kite/Gilead: Research Funding; Novartis: Research Funding; Oncternal: Research Funding; Oncternal: Research Funding; Clade Therapeutics: Membership on an entity's Board of Directors or advisory committees; Garuda Therapeutics: Membership on an entity's Board of Directors or advisory committees; LifeVault Bio: Membership on an entity's Board of Directors or advisory committees; Smart Immune: Membership on an entity's Board of Directors or advisory committees; TriArm Bio: Membership on an entity's Board of Directors or advisory committees.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH